Literature DB >> 34163170

Factors Influencing Lung Function in Patients with Cystic Fibrosis in Western Romania.

Mihaela Dediu1,2,3, Ioana Mihaiela Ciuca1,2,3, Monica Steluta Marc4, Estera Boeriu1, Liviu Laurentiu Pop1.   

Abstract

PURPOSE: The aim of this cross-sectional study was to identify the major factors influencing pulmonary function in CF patients from western side of Romania. PATIENTS AND METHODS: The study enrolled 51 patients with CF between the ages of 6 and 27.8 years who were monitored at regular visits to the National Cystic Fibrosis Centre and Pius Branzeu County Hospital in Timisoara, Romania, over a period of 2 years. The relationships between lung function, as measured by forced expiratory volume in 1 s (FEV1), with patient age, sex, body mass index (BMI), pancreatic insufficiency (PI), microbial infection, CF-related diabetes (CFRD), CF-associated liver disease (CFLD), and physical activity <30 min/day, were evaluated by multivariate regression analysis.
RESULTS: The results showed that FEV1 was 0.32% higher for each increase in percentile of BMI (95% confidence interval: 0.034-0.619). In addition, mean FEV1 was 1.52% lower with every year rise of age. PI and female sex increased the risk of impaired lung function (FEV1 <60%). The factors most closely correlated with pulmonary function in pediatric CF patients were current age (negative) and BMI (positive).
CONCLUSION: The findings of this study, in combination with what is known from other studies in CF, suggest that a better nutritional status and infection prophylaxis should be part of a comprehensive clinical management strategy for pediatric CF in Romania.
© 2021 Dediu et al.

Entities:  

Keywords:  cystic fibrosis; cystic fibrosis outcome; pediatric; respiratory disease

Year:  2021        PMID: 34163170      PMCID: PMC8214515          DOI: 10.2147/JMDH.S313209

Source DB:  PubMed          Journal:  J Multidiscip Healthc        ISSN: 1178-2390


Introduction

Cystic fibrosis (CF) is an autosomal recessive genetic disease in children1 that has serious adverse impacts on patients’ quality of life and life expectancy.2 CF is the most common potentially lethal monogenic disease in the Caucasian population and has variable clinical presentation,3 but usually progresses to chronic obstructive pulmonary disease with frequent pulmonary infections,4 chronic steatorrhea associated with exocrine pancreatic insufficiency (PI), liver disease or secondary diabetes.5 Osteopathy, nasal polyposis, chronic sinusitis, obstructive azoospermia,2,6 meconium ileus, rectal prolapse, and salt loss syndrome are possible manifestations or complications of CF.7 Lung disease is the major problem associated with CF in terms of prognosis and management.8 The clinical course of CF is influenced by frequent pulmonary exacerbations that cause structural and functional damage to the lungs,9 highlighting the importance of therapeutic interventions that preserve lung function.4 Factors affecting pulmonary function include patient age, body mass index (BMI)10,11 female sex, PI,12,13 CF-related diabetes (CFRD), CF-associated liver disease (CFLD),12 and respiratory bacterial infections14 requiring repeated and long courses of antibiotics.15 Because of a lack of neonatal screening in Romania, CF patients are diagnosed late, subsequently fail to thrive, and have an increased frequency of chronic infections in addition to altered lung function. A good clinical outcome for CF depends on improving lung function, which is difficult to achieve in Romania in the absence of modulator therapies. Considering that Romanian CF patients require a complete evaluation, the effect of factors influencing the lung function of our patients turn out to be important to be assessed. This was addressed in a cross-sectional study of a cohort of CF patients who were monitored over a 2-year period at the National Cystic Fibrosis Centre and Pius Branzeu County Hospital in Timisoara, Romania.

Materials and Methods

Patients

From May 2017 to June 2019, CF patients from Western Romania who regularly visited the National Cystic Fibrosis Centre in Romania were screened for eligibility to participate in the study. The inclusion criteria were as follows: patients with typical CF who were capable of performing the spirometry test, were not experiencing pulmonary exacerbation, and regularly visited the center. Patients who suffered an exacerbation in the last 3 months were not included. Patients and their guardians consented in writing to the use of their data for research purposes. The study was conducted in accordance with the principles of the Declaration of Helsinki, and was approved by the Ethics Committee of Pius Branzeu County Hospital (1145/2016).

Data Collection

At the time of study enrollment, we measured patients’ weight and height to calculate BMI according to US Centers for Disease Control and Prevention percentiles,16 collected bacteriologic samples, and carried out screening for CFLD and CFRD in accordance with national guidelines. Based on self-reported physical activity levels, the patients were classified as active (≥30 min/day of physical activity) or sedentary (physical activity for <30 min/day). Pulmonary function was assessed by spirometry; forced expiratory volume in 1 s (FEV1) was recorded as parameter related to lung function. FEV1 was used as the main index of lung function, and the best FEV1 value in each year was recorded for reference and categorized as follows: >80%, no obstruction (normal); 80–60%, mild obstruction; 40–59%, moderate obstruction and <40%, severe obstruction. No other FEV1 value was monitored in this study. Spirometry was performed outside of periods of exacerbation according to American Thoracic Society/European Respiratory Society standards, with Global Lung Function Initiative 2012 reference equations used to calculate predicted parameter values.17 Data on age at diagnosis of CF, Pseudomonas infection status and PI, also the patients genotypes were obtained from the center’s medical records.

Data Analysis

Multivariate regression analysis was performed to predict whether patient characteristics influence FEV1. The independent variables were current age, age at CF diagnosis, BMI, Pseudomonas aeruginosa infection, methicillin-resistant Staphylococcus aureus (MRSA) infection, PI, CFRD, CFLD, and physical activity. Quantitative data are expressed as mean ± standard deviation (SD) for continuous variables and as counts and percentages for categorical variables. Kolmogorov–Smirnov test was utilized to determinate the parametric and non-parametric data distribution and Mann–Whitney U-test, chi-square test and t-independent test were used to compare differences between the subgroups. To test the averages between two independent groups Mann–Whitney U-test (non-parametric data) was applied and t-independent test (parametric data). Chi-square test was used for comparison between independent groups with binomial data. Adjusted odds ratios (ORs) or risk ratios (RRs) with 95% confidence intervals (CIs) were calculated by univariate associations between patients with different outcomes and each predictor separately. Statistical analyses were performed with SPSS v20.0 for Windows (SPSS Inc, Chicago, IL, USA). A P value <0.05 was considered significant.

Results

Characteristics of the Study Population

A total of 51 patients aged between 6 and 27.8 years of age (mean ± SD: 13.7±5.7 years) were enrolled in the study. The characteristics of the patients are shown in Table 1. Most patients (89.5%) were clinically underweight, and the mean BMI percentile (±SD) was 19.2±22.1 (normal: 5th to 85th percentile). There was a slight majority of male patients (54.9%). A significant prevalence of F508del mutation exists in our population, as 52.9%, children were homozygous for F508del CFTR mutation, followed by 38% of compound heterozygous F508del/nonF508del and 9.1% with another genotype. The mean FEV1 (±SD) was 76%±21.3% (range: 33–127%).
Table 1

Characteristics of Patients by Age Category

CharacteristicAll Patients (n=51)Age 6–12 Years (n=25)Age 12–18 Years (n=15)Age >18 Years (n=11)
Sex
 Female23 (45.1)10 (40)7 (46.7)6 (54.5)
 Male28 (54.9)15 (60)8 (53.3)5 (45.5)
Current age13.79±5.769.36±1.9214.58±2.1622.76±3.54
Age at CF diagnosis4.49±4.911.98±2.164.45±4.3110.27±5.54
BMI kg/m2 (mean ± SD)16.32±2.6115.28±2.4917.02±2.0717.67±2.77
BMI percentile19.27±22.1924.52±24.5821.6±20.584.18±9.61
FEV1, %76±21.3282.92±15.8270.27±23.9168.09±14.16
Chronic infection
Pseudomonas27 (52.9)10 (40)8 (53.3)9 (81.8)
 MRSA10 (19.6)6 (24)2 (13.3)2 (18.2)
Pancreatic insufficiency42 (82.4)22 (88)12 (80)8 (72.7)
CFLD28 (54.9)11 (44)11 (73.3)6 (54.5)
CFRD5 (9.8)1 (4)1 (6.7)3 (27.3)
Physical activity <30 min/day21 (41.2)11 (44)6 (40)4 (36.4)

Notes: Data are presented as mean±standard deviation or n (%) unless otherwise indicated.

Abbreviations: BMI, body mass index; CF, cystic fibrosis; CFLD, cystic fibrosis-associated liver disease; CFRD, cystic fibrosis-related diabetes; FEV1, forced expiratory volume in 1 s; MRSA, methicillin-resistant Staphylococcus aureus.

Characteristics of Patients by Age Category Notes: Data are presented as mean±standard deviation or n (%) unless otherwise indicated. Abbreviations: BMI, body mass index; CF, cystic fibrosis; CFLD, cystic fibrosis-associated liver disease; CFRD, cystic fibrosis-related diabetes; FEV1, forced expiratory volume in 1 s; MRSA, methicillin-resistant Staphylococcus aureus.

Multivariate Regression Analysis of Patient Factors Influencing Pulmonary Function

Multivariate regression analysis was performed to predict whether patient characteristics influence FEV1. The independent variables were current age, age at CF diagnosis, BMI, Pseudomonas aeruginosa infection, methicillin-resistant Staphylococcus aureus (MRSA) infection, PI, CFRD, CFLD, and physical activity. These factors explained 30% of the variability in the FEV1 value (r2= 0.301). The results of the multivariate regression analysis are summarized in Table 2.
Table 2

Results of the Multivariate Regression Analysis of the Effects of Different Variables on FEV1

VariableUnstandardized CoefficientsStandardized CoefficienttSignificance95% CI for B
Lower BoundUpper Bound
BSEB
(Constant)87.97614.2586.1700.00059.15116.79
Sex2.6986.5780.0640.4100.684−10.515.99
Current age−1.5240.724−0.412−2.1040.042−2.98−0.06
Age at CF diagnosis1.5210.8490.3501.7900.081−0.193.23
BMI percentile0.3270.1450.3402.2530.0300.0340.61
Chronic Pseudomonas infection−11.2136.464−0.265−1.7350.090−24.271.85
Chronic MRSA infection−1.5247.539−0.029−0.2020.841−16.7613.71
Pancreatic insufficiency0.6629.0800.0120.0730.942−17.6819.01
CFLD−0.1507.018−0.004−0.0210.983−14.3314.03
CFRD10.05910.5030.1420.9580.344−11.1631.28
Physical activity <30 min/day−1.8956.860−0.044−0.2760.784−15.7511.96

Abbreviations: BMI, body mass index; CF, cystic fibrosis; CFLD, cystic fibrosis-associated liver disease; CFRD, cystic fibrosis-related diabetes; CI, confidence interval; FEV1, forced expiratory volume in 1 s; MRSA, methicillin-resistant Staphylococcus aureus; SE, standard error.

Results of the Multivariate Regression Analysis of the Effects of Different Variables on FEV1 Abbreviations: BMI, body mass index; CF, cystic fibrosis; CFLD, cystic fibrosis-associated liver disease; CFRD, cystic fibrosis-related diabetes; CI, confidence interval; FEV1, forced expiratory volume in 1 s; MRSA, methicillin-resistant Staphylococcus aureus; SE, standard error. The regression model revealed a significant effect of patients’ current age (P= 0.04) and BMI (P= 0.03) on lung function: average FEV1 was 1.52% lower for higher ages (95% CI: −2.98 to −0.06). Although a negative association was found between current age and FEV1 (B= −1.52, p= 0.04), almost the same association was observed between age at CF diagnosis and FEV1 value but in a positive way (B= 1.52, p= 0.081), with no statistical significance. The relationship between BMI and FEV1 was positive: a higher BMI was associated with a higher average FEV1%; mean FEV1 was 0.32% higher for each percentile of BMI (95% confidence interval: 0.03–0.61). No significant correlations were found between age at CF diagnosis (p= 0.081), P. aeruginosa (p= 0.09), MRSA infection (p= 0.841), PI (p= 0.942), CFRD (p= 0.244), CFLD (p= 0.983), or decreased physical activity (p=0.784) and lung function (Table 2).

Risk Factors for Pulmonary Dysfunction in Pediatric CF

Nearly half of patients (49.01%) had good lung function (FEV1 >80%) (Table 3). Patients with moderate or severe obstruction (FEV1 <60%) were diagnosed with CF at a later age (6.7±4.7 years) than those with mild obstruction (FEV1=60–80%; 3.02±3.7 years) or normal lung function (FEV1 >80%; 4.4±5.3 years). Additionally, the percentage of patients with chronic Pseudomonas infection was higher in the FEV1 <60% group (72.7%) compared to the group with normal lung function (40%). Evaluating the subgroup patients with FEV1<60%, we noticed that more than half of patients (54.5%) were F508 homozygous, another 36.4% heterozygous for F508, a significant predominance of 90% for F508del mutation. Only 9.1% of patients with impaired lung function had non F508del genotypes.
Table 3

Characteristics of Patients by FEV1 Category

CharacteristicFEV1 <60%a (n=11)FEV1=60%–80%b (n=15)FEV1 >80%c (n=25)
Sex
 Female6 (54.5)7 (46.7)10 (40)
 Male5 (45.5)8 (53.3)15 (60)
Current age18.62±6.2811.79±4.2212.86±5.32
Age at CF diagnosis6.7±4.723.02±3.764.41±5.39
BMI percentile9±12.3916.8±21.2925.28±24.65
FEV1, %44±7.0570.53±5.4893.36±10.33
Chronic infection
Pseudomonas8 (72.7)9 (60)10 (40)
 MRSA2 (18.2)3 (20)5 (20)
Pancreatic insufficiency8 (72.7)15 (100)19 (76)
CFLD7 (63.6)8 (53.3)13 (52)
CFRD1 (9.1)1 (6.7)3 (12)
Physical activity <30 min/day4 (36.4)8 (53.3)9 (36)

Notes: Data are presented as mean±standard deviation or n (%) unless otherwise indicated. aModerate to severe obstruction; bMild obstruction; cNo obstruction (normal lung function).

Abbreviations: BMI, body mass index; CF, cystic fibrosis; CFLD, cystic fibrosis-associated liver disease; CFRD, cystic fibrosis-related diabetes; FEV1, forced expiratory volume in 1 s; MRSA, methicillin-resistant Staphylococcus aureus.

Characteristics of Patients by FEV1 Category Notes: Data are presented as mean±standard deviation or n (%) unless otherwise indicated. aModerate to severe obstruction; bMild obstruction; cNo obstruction (normal lung function). Abbreviations: BMI, body mass index; CF, cystic fibrosis; CFLD, cystic fibrosis-associated liver disease; CFRD, cystic fibrosis-related diabetes; FEV1, forced expiratory volume in 1 s; MRSA, methicillin-resistant Staphylococcus aureus. There were statistically significant differences between patients with FEV1 <60% and those with normal lung function in terms of current age 18.6 years versus 12.8 years (P=0.008) and BMI percentile (P=0.041). Patients with FEV1 <60% had a lower BMI percentile than those with FEV1 >80% (9±12.3 vs 25.2±24.6) and were older (18.6±6.2 vs 12.86±5.3 years). The mean FEV1 in patients with moderate or severe obstruction was almost half the value of those with normal lung function (44%±7.05% vs 93.3%±10.3%). About one-fifth of patients (21.56%) had moderate or severe obstruction; associated factors included chronic Pseudomonas infection, female sex, and physical activity <30 min/day. Patients with chronic Pseudomonas infection were at 2.3 times higher risk for poor lung function (FEV1 <60%) than uninfected children (Table 4).
Table 4

Relative Risk and Odds Ratio for FEV1 <60%

VariableRR95% CIOR95% CI
Lower BoundUpper BoundLower BoundUpper Bound
Female sex1.460.514.171.620.426.21
F508 allele1.090.176.821.110.1111.08
Chronic Pseudomonas infection2.370.77.932.940.6812.75
Chronic MRSA infection1.090.274.301.120.206.26
Pancreatic insufficiency1.750.575.332.120.4310.37
CFLD0.690.232.080.630.152.50
CFRD1.080.176.821.110.1111.08
Physical activity <30 min/day1.220.413.661.290.325.13

Abbreviations: CFLD, cystic fibrosis-associated liver disease; CFRD, cystic fibrosis-related diabetes; CI, confidence interval; FEV1, forced expiratory volume in 1 s; MRSA, methicillin-resistant Staphylococcus aureus; OR, odds ratio; RR, relative risk.

Relative Risk and Odds Ratio for FEV1 <60% Abbreviations: CFLD, cystic fibrosis-associated liver disease; CFRD, cystic fibrosis-related diabetes; CI, confidence interval; FEV1, forced expiratory volume in 1 s; MRSA, methicillin-resistant Staphylococcus aureus; OR, odds ratio; RR, relative risk. PI, female sex, F508 del homozygous genotype and physical activity <30 min/day increased the risk for FEV1 <60% (RR for PI=1.75, 95% CI: 0.57 to 0.53; RR for female sex=1.46, 95% CI: 0.51 to 4.17; RR for F508del =1.09 95% CI: 0.11–11.8 and RR for physical activity <30 min/day=1.22, 95% CI: 0.41 to 3.66) (Table 4). Chronic MRSA infection (RR=1.09, 95% CI: 0.27 to 4.3) and CFRD (RR=1.08, 95% CI: 0.17 to 6.82) had a weak influence on the probability of FEV1 <60%, but CFLD was not a risk factor (RR=0.69). Chronic Pseudomonas infection was present in 52.9% of the patients; these patients had a significantly lower FEV1 than those without infection (70.8±23.8 vs 81.7±16.7) (Table 5), and almost similar BMI (20.3 compared to 18.08). The rate of chronic Pseudomonas infection was higher in females (OR=1.79, 95% CI: 0.58 to 5.49) and in patients with impaired lung function (FEV1 <80%; OR=2.83, 95% CI: 0.9 to 8.83).
Table 5

Characteristics of Patients with Chronic Pseudomonas Infection and Uninfected Patients

CharacteristicPseudomonas Infectionp value
Yes (n=27)No (n=24)
Sex
 Female14 (51.9)9 (37.5)1
 Male13 (48.1)15 (62.5)1
Current age15.26±6.1212.13±4.950.057
Age at CF diagnosis5.88±5.682.93±3.330.1
BMI percentile20.33±23.4318.08±21.140.992
FEV1, %70.85±23.8381.79±16.720.042
Chronic MRSA infection6 (22.2)4 (16.7)0.444
Pancreatic insufficiency23 (85.2)19 (79.2)0.421
CFLD18 (66.7)10 (41.7)0.076
CFRD3 (11.1)2 (8.3)0.742
Physical activity <30 min/day11 (40.7)10 (41.7)0.947

Notes: Data are presented as mean±standard deviation or n (%) unless otherwise indicated.

Abbreviations: BMI, body mass index; CFLD, cystic fibrosis-associated liver disease; CFRD, cystic fibrosis-related diabetes; FEV1, forced expiratory volume in 1 s; MRSA, methicillin-resistant Staphylococcus aureus.

Characteristics of Patients with Chronic Pseudomonas Infection and Uninfected Patients Notes: Data are presented as mean±standard deviation or n (%) unless otherwise indicated. Abbreviations: BMI, body mass index; CFLD, cystic fibrosis-associated liver disease; CFRD, cystic fibrosis-related diabetes; FEV1, forced expiratory volume in 1 s; MRSA, methicillin-resistant Staphylococcus aureus.

Discussion

This is the first study evaluating factors affecting lung function in Romanian pediatric patients with cystic fibrosis presenting the relation of different risk factors with the lung function. The lack of neonatal screening in Romania associates a delayed diagnosis, when secondary complications like failure to thrive and chronic infections alter lung function. FEV1 is an important parameter in the evaluation of lung function.18 The FEV1 values in our cohort varied, ranging from severe obstruction (FEV1 <40%) in a few patients to a relatively normal value of 78%. Moderate or severe obstruction was observed in a substantial proportion of our patients (21.56%), indicating that intervention was urgently needed. We investigated whether factors known to influence lung function in CF would be significant in our pediatric cohort using a multivariate regression model. PI had no influence on lung function (P=0.942, Table 2), possibly because most of our patients had PI, which is typical in classic forms of CF.19 In the general study population, using the multivariate regression model, no statistical influence of PI was found (p=0.92) on the FEV1 of all patients, as the combined effect of all factors included in the multivariate model was assessed. Yet, the calculation of the risk factors for the subgroup of patients with lower FEV1<60% showed that patients with PI have a higher risk of 1.75 RR for a lower pulmonary function. Physical activity level had no significant effect on FEV1 in our multivariate analysis, although increased activity has been shown to improve clinical outcome in CF patients.20 Nevertheless, the physical activity <30 min/day associate an impaired lung function of FEV1 <60% (RR=1.22, 95% CI: 0.41 to 3.66), revealing thar low FEV1 is associated with a decrease activity level because of fatigability. Also, the F508 del homozygous genotype was a risk factor among patients with FEV1<60%, as expected and similar with previous other studies.12,13 However, we observed significant relationships between patients’ BMI (P=0.03), current age (P=0.04) and lung function, evaluated by multivariate regression analysis, consistent with previous findings.12,21 Nearly all of our patients (almost 90%) were underweight (BMI <20 kg/m2), with low mean BMI percentile of 19.27±22.19; although we intended to carry out a weight gain intervention, none of our patients accepted enteral nutrition because of anxiety pertaining to gastrostomy. The link between nutritional status and lung function has been previously reported by several studies,22,23 with a higher BMI being associated with better lung function.12 Although it was previously demonstrated that earlier diagnosis has better outcomes for patients with CF,12 in our study, age at diagnosis was unrelated to FEV1 (P= 0.081, Table 2). However, the current age of patients was negatively correlated with FEV1 that is, older patients had worse lung function. Indeed, mean FEV1 was 1.52% lower (95% CI: −2.98 to −0.06) for every 1-year of age, in agreement with earlier findings.23,24 Thus, older and thinner children are at greater risk for poor lung function, with a mean FEV1 value that is half of that in younger patients with normal BMI. Chronic Pseudomonas infection was present in more than half of our patients and was associated with a lower FEV1 compared to uninfected patients. Chronic Pseudomonas infection, PI, female sex, and physical activity <30 min/day were significant risk factors for FEV1 <60%, as reported in other studies.12,17,22 Differing to published observations, we did not find any association between CFRD12,23 or MRSA infection25–27 and lung function in our cohort, although female patients with PI and chronic Pseudomonas infection had a higher risk of FEV1 <60%, as previously reported.28 A possible explanation for these discrepancies is the small sample size of our study or, in the case of MRSA infection, the prevalence of a less aggressive MRSA strain in our patients than that described by others.29 The clinical and functional outcome of CF patients was found to decline after the development of diabetes,30 but in our study CFRD was unrelated to FEV1 (P= 0.344) in the multivariate regression analysis and was not a significant risk factor (RR=1.08, Table 4) for poor lung function. The same was true for CFLD, which did not have a significant effect on FEV1 (P= 0.983, Table 2) or constitute a risk factor for FEV1 <60% (RR= 0.69), although it is known to affect the life expectancy of CF patients.5

Conclusion

In conclusion, the results of our study demonstrate that patients’ BMI and current age had a significant association with FEV1 in our patients. We also identified chronic Pseudomonas infection, PI, female sex, and physical activity <30 min/day as risk factors for reduced lung function (FEV1 <60%) in our cohort. Although the study population was relatively small, the results allowed us to take immediate action to improve patients’ clinical status and outcome. The potentially modifiable factor affecting lung function—and thus, life expectancy—in these patients is BMI, which can be increased through weight gain interventions. Additionally, given that chronic Pseudomonas infection was also a risk factor for poor lung function, a strategy should be implemented to prevent infections, a supplementary monthly bacteriological examination was included in our practice in children with impaired lung function or low BMI. In summary, improvement of nutritional status and a more active lifestyle with infection prophylaxis are the primary treatment goals for our pediatric CF patient population.
  29 in total

1.  Treatment decisions for MRSA in patients with cystic fibrosis (CF): when is enough, enough?

Authors:  Scott C Bell; Patrick A Flume
Journal:  Thorax       Date:  2017-01-11       Impact factor: 9.139

Review 2.  Diagnosis and treatment of intestinal malabsorption in cystic fibrosis.

Authors:  James M Littlewood; Susan P Wolfe; Steven P Conway
Journal:  Pediatr Pulmonol       Date:  2006-01

3.  Cystic fibrosis liver disease - from diagnosis to risk factors.

Authors:  Ioana Mihaiela Ciucă; Liviu Pop; Liviu Tămaş; Sorina Tăban
Journal:  Rom J Morphol Embryol       Date:  2014       Impact factor: 1.033

4.  Prevalence and impact on FEV(1) decline of chronic methicillin-resistant Staphylococcus aureus (MRSA) colonization in patients with cystic fibrosis. A single-center, case control study of 165 patients.

Authors:  E Vanderhelst; L De Meirleir; S Verbanck; D Piérard; W Vincken; A Malfroot
Journal:  J Cyst Fibros       Date:  2011-09-09       Impact factor: 5.482

Review 5.  Cystic fibrosis.

Authors:  Felix Ratjen; Gerd Döring
Journal:  Lancet       Date:  2003-02-22       Impact factor: 79.321

Review 6.  Exercise and physical activity in children with cystic fibrosis.

Authors:  Donna L Wilkes; Jane E Schneiderman; Thanh Nguyen; Liane Heale; Fiona Moola; Felix Ratjen; Allan L Coates; Greg D Wells
Journal:  Paediatr Respir Rev       Date:  2009-07-21       Impact factor: 2.726

Review 7.  Treatment of lung infection in patients with cystic fibrosis: current and future strategies.

Authors:  Gerd Döring; Patrick Flume; Harry Heijerman; J Stuart Elborn
Journal:  J Cyst Fibros       Date:  2012-11-06       Impact factor: 5.482

8.  The European Cystic Fibrosis Society Patient Registry: valuable lessons learned on how to sustain a disease registry.

Authors:  Laura Viviani; Anna Zolin; Anil Mehta; Hanne Vebert Olesen
Journal:  Orphanet J Rare Dis       Date:  2014-06-07       Impact factor: 4.123

9.  A Different Microbiome Gene Repertoire in the Airways of Cystic Fibrosis Patients with Severe Lung Disease.

Authors:  Giovanni Bacci; Alessio Mengoni; Ersilia Fiscarelli; Nicola Segata; Giovanni Taccetti; Daniela Dolce; Patrizia Paganin; Patrizia Morelli; Vanessa Tuccio; Alessandra De Alessandri; Vincenzina Lucidi; Annamaria Bevivino
Journal:  Int J Mol Sci       Date:  2017-07-29       Impact factor: 5.923

10.  Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality.

Authors:  Antoinette Moran; Jordan Dunitz; Brandon Nathan; Asad Saeed; Bonnie Holme; William Thomas
Journal:  Diabetes Care       Date:  2009-06-19       Impact factor: 19.112

View more
  2 in total

Review 1.  Antibiotherapy in Children with Cystic Fibrosis-An Extensive Review.

Authors:  Ioana Mihaiela Ciuca; Mihaela Dediu; Diana Popin; Liviu Laurentiu Pop; Liviu Athos Tamas; Ciprian Nicolae Pilut; Bogdan Almajan Guta; Zoran Laurentiu Popa
Journal:  Children (Basel)       Date:  2022-08-20

2.  The Relation between Vitamin D Level and Lung Clearance Index in Cystic Fibrosis-A Pilot Study.

Authors:  Mihaela Dediu; Ioana Mihaiela Ciuca; Liviu Laurentiu Pop; Daniela Iacob
Journal:  Children (Basel)       Date:  2022-03-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.